Cargando…

Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation

Bcl-x pre-mRNA splicing serves as a typical example to study the impact of alternative splicing in the modulation of cell death. Dysregulation of Bcl-x apoptotic isoforms caused by precarious equilibrium splicing is implicated in genesis and development of multiple human diseases, especially cancers...

Descripción completa

Detalles Bibliográficos
Autores principales: Dou, Zhihui, Zhao, Dapeng, Chen, Xiaohua, Xu, Caipeng, Jin, Xiaodong, Zhang, Xuetian, Wang, Yupei, Xie, Xiaodong, Li, Qiang, Di, Cuixia, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196531/
https://www.ncbi.nlm.nih.gov/pubmed/34118966
http://dx.doi.org/10.1186/s13046-021-02001-w
_version_ 1783706708372094976
author Dou, Zhihui
Zhao, Dapeng
Chen, Xiaohua
Xu, Caipeng
Jin, Xiaodong
Zhang, Xuetian
Wang, Yupei
Xie, Xiaodong
Li, Qiang
Di, Cuixia
Zhang, Hong
author_facet Dou, Zhihui
Zhao, Dapeng
Chen, Xiaohua
Xu, Caipeng
Jin, Xiaodong
Zhang, Xuetian
Wang, Yupei
Xie, Xiaodong
Li, Qiang
Di, Cuixia
Zhang, Hong
author_sort Dou, Zhihui
collection PubMed
description Bcl-x pre-mRNA splicing serves as a typical example to study the impact of alternative splicing in the modulation of cell death. Dysregulation of Bcl-x apoptotic isoforms caused by precarious equilibrium splicing is implicated in genesis and development of multiple human diseases, especially cancers. Exploring the mechanism of Bcl-x splicing and regulation has provided insight into the development of drugs that could contribute to sensitivity of cancer cells to death. On this basis, we review the multiple splicing patterns and structural characteristics of Bcl-x. Additionally, we outline the cis-regulatory elements, trans-acting factors as well as epigenetic modifications involved in the splicing regulation of Bcl-x. Furthermore, this review highlights aberrant splicing of Bcl-x involved in apoptosis evade, autophagy, metastasis, and therapy resistance of various cancer cells. Last, emphasis is given to the clinical role of targeting Bcl-x splicing correction in human cancer based on the splice-switching oligonucleotides, small molecular modulators and BH3 mimetics. Thus, it is highlighting significance of aberrant splicing isoforms of Bcl-x as targets for cancer therapy.
format Online
Article
Text
id pubmed-8196531
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81965312021-06-15 Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation Dou, Zhihui Zhao, Dapeng Chen, Xiaohua Xu, Caipeng Jin, Xiaodong Zhang, Xuetian Wang, Yupei Xie, Xiaodong Li, Qiang Di, Cuixia Zhang, Hong J Exp Clin Cancer Res Review Bcl-x pre-mRNA splicing serves as a typical example to study the impact of alternative splicing in the modulation of cell death. Dysregulation of Bcl-x apoptotic isoforms caused by precarious equilibrium splicing is implicated in genesis and development of multiple human diseases, especially cancers. Exploring the mechanism of Bcl-x splicing and regulation has provided insight into the development of drugs that could contribute to sensitivity of cancer cells to death. On this basis, we review the multiple splicing patterns and structural characteristics of Bcl-x. Additionally, we outline the cis-regulatory elements, trans-acting factors as well as epigenetic modifications involved in the splicing regulation of Bcl-x. Furthermore, this review highlights aberrant splicing of Bcl-x involved in apoptosis evade, autophagy, metastasis, and therapy resistance of various cancer cells. Last, emphasis is given to the clinical role of targeting Bcl-x splicing correction in human cancer based on the splice-switching oligonucleotides, small molecular modulators and BH3 mimetics. Thus, it is highlighting significance of aberrant splicing isoforms of Bcl-x as targets for cancer therapy. BioMed Central 2021-06-12 /pmc/articles/PMC8196531/ /pubmed/34118966 http://dx.doi.org/10.1186/s13046-021-02001-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Dou, Zhihui
Zhao, Dapeng
Chen, Xiaohua
Xu, Caipeng
Jin, Xiaodong
Zhang, Xuetian
Wang, Yupei
Xie, Xiaodong
Li, Qiang
Di, Cuixia
Zhang, Hong
Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation
title Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation
title_full Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation
title_fullStr Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation
title_full_unstemmed Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation
title_short Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation
title_sort aberrant bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196531/
https://www.ncbi.nlm.nih.gov/pubmed/34118966
http://dx.doi.org/10.1186/s13046-021-02001-w
work_keys_str_mv AT douzhihui aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation
AT zhaodapeng aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation
AT chenxiaohua aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation
AT xucaipeng aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation
AT jinxiaodong aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation
AT zhangxuetian aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation
AT wangyupei aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation
AT xiexiaodong aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation
AT liqiang aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation
AT dicuixia aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation
AT zhanghong aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation